Unknown

Dataset Information

Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.


ABSTRACT:

Background

Concern about costs and antiretroviral therapy (ART)-associated toxicities led to the consideration of CD4 driven strategies for the management of HIV. That approach was evaluated in the SMART trial that reported an unexpected increase of cardiovascular events after treatment interruption (TI). Our goal was to evaluate fasting metabolic changes associated with interruption of antiretroviral therapy and relate them to changes of immune activation markers and cardiovascular risk.

Methodology

ACTG 5102 enrolled 47 HIV-1-infected subjects on stable ART, with <200 HIV RNA copies/mL and CD4 cell count >or=500 cells/microL. Subjects were randomly assigned to continue ART for 18 weeks with or without 3 cycles of interleukin-2 (IL-2) (cycle = 4.5 million IU sc BID x 5 days

SUBMITTER: Tebas P 

PROVIDER: S-EPMC2292263 | biostudies-literature | 2008 Apr

REPOSITORIES: biostudies-literature